185 related articles for article (PubMed ID: 22544005)
21. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Citrome L; Jaffe A; Levine J; Allingham B; Robinson J
Psychiatr Serv; 2004 Sep; 55(9):1006-13. PubMed ID: 15345760
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
23. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
Misiak B; Frydecka D; Łaczmański Ł; Ślęzak R; Kiejna A
Eur J Clin Pharmacol; 2014 Dec; 70(12):1433-41. PubMed ID: 25291992
[TBL] [Abstract][Full Text] [Related]
24. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
[TBL] [Abstract][Full Text] [Related]
25. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
[TBL] [Abstract][Full Text] [Related]
26. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
[TBL] [Abstract][Full Text] [Related]
27. Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.
O'Donoghue B; Schäfer MR; Becker J; Papageorgiou K; Amminger GP
Early Interv Psychiatry; 2014 Aug; 8(3):276-80. PubMed ID: 23968390
[TBL] [Abstract][Full Text] [Related]
28. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
29. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.
Birkenaes AB; Birkeland KI; Friis S; Opjordsmoen S; Andreassen OA
J Clin Psychopharmacol; 2009 Apr; 29(2):109-16. PubMed ID: 19512971
[TBL] [Abstract][Full Text] [Related]
30. Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.
Tsuneyama N; Suzuki Y; Sawamura K; Sugai T; Fukui N; Watanabe J; Ono S; Saito M; Someya T
PLoS One; 2016; 11(3):e0149518. PubMed ID: 26930407
[TBL] [Abstract][Full Text] [Related]
31. [Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disorders].
Iagubov MI; Shtark LN
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9 Pt 2):57-60. PubMed ID: 22027609
[TBL] [Abstract][Full Text] [Related]
32. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
33. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
34. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
[TBL] [Abstract][Full Text] [Related]
36. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
Atmaca M; Kuloglu M; Tezcan E; Gecici O; Ustundag B
Schizophr Res; 2003 Mar; 60(1):99-100. PubMed ID: 12505146
[No Abstract] [Full Text] [Related]
37. Quetiapine treatment in youth is associated with decreased insulin secretion.
Ngai YF; Sabatini P; Nguyen D; Davidson J; Chanoine JP; Devlin AM; Lynn FC; Panagiotopoulos C
J Clin Psychopharmacol; 2014 Jun; 34(3):359-64. PubMed ID: 24633003
[TBL] [Abstract][Full Text] [Related]
38. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
39. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
40. [Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].
Birkás Kováts D; Palik E; Faludi G; Cseh K
Neuropsychopharmacol Hung; 2005 Sep; 7(3):132-9. PubMed ID: 16493877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
